Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

TESARO Announces Lonnie Moulder and Mary Lynne Hed

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 32)
Posted On: 06/28/2017 10:00:20 AM
Avatar
Posted By: News Desk 2018
TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year ® in Life Sciences Development for the New England program. The awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities.

“On behalf of all TESARO associates, we are honored to accept this award in support of people bravely facing cancer. They are at the heart of our mission, and everything we do each and every day is for the patients we serve,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “We are grateful to be in a position where we can make a meaningful difference in the lives of patients. This award is a true validation of the work TESARO associates are doing each and every day.”

“The company’s success to date would not have been possible without the drive and collaboration of TESARO associates and the strategic partnerships we’ve developed across advocacy, industry and academia,” said Lonnie Moulder, CEO of TESARO. “We are honored and humbled to accept the EY Entrepreneur of the Year New England Award on behalf of this talented group of individuals. It is truly a team effort to accomplish what we have over a relatively short period of time.”

In the seven years since TESARO’s founding, the company has made significant contributions to patient care through rapid and responsible product development and commercialization. Since 2010, TESARO has grown to become a leading oncology-focused biopharmaceutical company with more than 650 associates across the U.S. and Europe. TESARO has launched two important oncology medicines and built out a robust pipeline of oncology and immuno-oncology candidates, three of which are currently under review in both the U.S. and Europe.

All regional award winners will move on for consideration in the Entrepreneur of the Year National program. Award winners in several national categories, as well as the Entrepreneur of the Year National Overall Award winner, will be announced at the Entrepreneur of the Year National Awards on November 18, 2017. The awards are the culminating event of the Strategic Growth Forum™, the nation’s most prestigious gathering of high-growth, market-leading companies.

About EY Entrepreneur of the Year® EY Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com , and follow us on Twitter and LinkedIn .

 

Investor/Media Contact: Jennifer Davis Vice President, Corporate Affairs & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us